Zambon
Italy - BressoBiotechnology
Focus: Zambon is an Italian specialty pharma company founded in 1906 focused on small molecules across ophthalmology and cardiovascular therapeutic areas. The company is heavily dependent on a single product (MONUROL) for revenue generation.
Profile data last refreshed 18h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Zambon
AI assessmentNot HiringNo open roles listed right now. Follow Zambon to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Zambon's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
9 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$79K Part DDeclining
LOE Approaching
Only revenue-generating product; single-dose antibiotic for acute cystitis facing patent expiration with no clear succession product.
Help build intelligence for Zambon
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.